HIV, Drug Use, Sexual Risk
HIV, Drug Use, Sexual Risk is a research topic within Epidemiology. Science Explorer counts 31k research works in it since 1955. 21.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the global epidemiology of HIV among injection drug users, with an emphasis on harm reduction strategies, respondent-driven sampling methodology, and the impact of the risk environment on HIV transmission. The papers also address the effectiveness of needle exchange programs and other interventions for reducing HIV risk among people who inject drugs.
- HIV
- drug use
- harm reduction
- injection drug users
- respondent-driven sampling
- public health
- risk environment
- needle exchange programs
- substance abuse
- epidemiology
- Research works
- 31k fractional, since 1955
- In the world top 10%
- 6.8k per year above
- Top-10% rate
- 21.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +29% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead HIV, Drug Use, Sexual Risk research?
By volume, the United States and Canada publish the most (2.6k and 412 works in 2022–2025).
By volume, 2022–2025
- 1 United States 2.6k works
- 2 Canada 412 works
- 3 United Kingdom 362 works
- 4 Australia 237 works
- 5 China 209 works
- 6 India 170 works
- 7 Brazil 142 works
- 8 France 136 works
- 9 South Africa 127 works
- 10 Spain 108 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead HIV, Drug Use, Sexual Risk research?
By volume in 2022–2025, University of North Carolina at Chapel Hill publishes the most HIV, Drug Use, Sexual Risk research, followed by Johns Hopkins University and UNSW Sydney.
By volume, 2022–2025
- 1 University of North Carolina at Chapel HillUnited States 126 works
- 2 Johns Hopkins UniversityUnited States 81 works
- 3 UNSW SydneyAustralia 45 works
- 4 University of WashingtonUnited States 40 works
- 5 New York UniversityUnited States 40 works
- 6 University of California, San FranciscoUnited States 38 works
- 7 Yale UniversityUnited States 38 works
- 8 Columbia UniversityUnited States 34 works
- 9 Emory UniversityUnited States 33 works
- 10 University of British ColumbiaCanada 32 works
Who are the leading researchers in HIV, Drug Use, Sexual Risk?
The most-cited researchers publishing on HIV, Drug Use, Sexual Risk include Bach Xuan Tran, Louisa Degenhardt and Till Bärnighausen.
- 1 Bach Xuan Tran Vietnam 8.2k citations
- 2 Louisa Degenhardt Australia 5.7k citations
- 3 Till Bärnighausen Germany 5.4k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is HIV, Drug Use, Sexual Risk research done?
The largest centres of HIV, Drug Use, Sexual Risk research in 2022–2025 are New York (United States), London (United Kingdom), Chapel Hill (United States) and Baltimore (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Kampala, Providence and Chapel Hill.
Largest cities, 2022–2025
- 1 New York United States 167 works
- 2 London United Kingdom 131 works
- 3 Chapel Hill United States 129 works
- 4 Baltimore United States 128 works
- 5 Boston United States 112 works
- 6 Atlanta United States 111 works
- 7 Toronto Canada 84 works
- 8 Vancouver Canada 81 works
- 9 Washington D.C. United States 73 works
- 10 Melbourne Australia 68 works
Where it is the local speciality
- KampalaUG · 36.5 works14×
- ProvidenceUS · 50.2 works14×
- Chapel HillUS · 128.6 works12×
- BurnabyCA · 20.7 works11×
- VancouverCA · 80.8 works10×
- LexingtonUS · 27.7 works9.5×
- BaltimoreUS · 128.4 works9.0×
- San FranciscoUS · 66.2 works8.6×
Location quotient: how much more of its research is in HIV, Drug Use, Sexual Risk than the world average.
Where is the best place to study HIV, Drug Use, Sexual Risk?
Among universities, judged by research, University of Victoria, Boston University and London School of Hygiene & Tropical Medicine score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | University of VictoriaCanada | 75.3 | 37.6% | 10.2× | 14 | +171.5% |
| 2 | Boston UniversityUnited States | 63.9 | 29.2% | 9.7× | 28 | +75.0% |
| 3 | London School of Hygiene & Tropical MedicineUnited Kingdom | 63.3 | 25.4% | 22.7× | 20 | +32.0% |
| 4 | Johns Hopkins UniversityUnited States | 62.4 | 21.4% | 12.9× | 81 | +30.3% |
| 5 | University of California, San FranciscoUnited States | 61.2 | 25.3% | 10.2× | 38 | +46.2% |
| 6 | Brown UniversityUnited States | 60.6 | 24.0% | 12.6× | 29 | +89.4% |
| 7 | La Trobe UniversityAustralia | 60.1 | 26.6% | 8.1× | 14 | +169.2% |
| 8 | Simon Fraser UniversityCanada | 59.5 | 26.5% | 12.3× | 20 | +49.5% |
| 9 | New York UniversityUnited States | 58.3 | 27.3% | 8.5× | 40 | +34.7% |
| 10 | UNSW SydneyAustralia | 58.0 | 22.6% | 9.3× | 46 | +7.6% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is HIV, Drug Use, Sexual Risk research growing?
Output in 2018–2022 was 29% higher than in 2013–2017, peaking in 2020. The fastest-growing topics are HIV, Drug Use, Sexual Risk.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.